ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Phase 1 Terminated 6 enrolled Celgene Corporation

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly and every 3-weeks ABI-007 in combination with carboplatin (area under the curve \[AUC\]=6) in patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.

Timeline

Start: 2006-11-01
Primary completion: 2008-02-01
Completion: 2008-02-01

Outcome

Outcome not reported

Stopped: “MTD not determined”

Publications

Hafner C, Windpassinger M, Tretter EV, Rebernig KA, Reindl SM, Hochreiter B, Dekan S, Haider P, Kiss H, Klein KU, Wohlrab P. Role of mitochondrial DNA level in epidural-related maternal fever: a single-centre, observational, pilot study. BMC Pregnancy Childbirth. 2024 May 3;24(1):341. doi: 10.1186/s12884-024-06551-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABI-007	Unknown	80 mg/m2	Intravenous
Subject	ABI-007	Unknown	150 mg/m2	Intravenous
Background	Carboplatin	Small molecule	—	Intravenous